{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T20:35:21Z","timestamp":1790714121080,"version":"4.1.0"},"reference-count":24,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,10,5]],"date-time":"2022-10-05T00:00:00Z","timestamp":1664928000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:sec><jats:title>Background and purpose<\/jats:title><jats:p>Anti-titin antibodies are antistriational antibodies associated with thymoma-associated myasthenia gravis (MG). We evaluated whether the patients with anti-titin antibody are more frequently hospitalized to manage thymoma-associated MG than those patients without anti-titin antibody.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Patients with thymoma-associated MG who conducted the serological test for anti-titin antibody were retrospectively included. Disease severity, treatments, MG-related annual hospitalization rate, and MG-related emergency room (ER) visit rate were compared between the patients with anti-titin antibody and those patients without anti-titin antibody. Multivariate analysis was conducted to analyze the association between anti-titin antibody serostatus and multiple admissions (hospitalization or ER visit of \u22652 times).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Of the 64 included patients, 31 (48.4%) patients were positive for anti-titin antibody (titin+ group) and 33 (51.6%) patients were negative for anti-titin antibody (titin\u2013 group). Both the annual rate of MG-related hospitalization and ER visit were significantly higher in the titin+ group [0.2 (0.1\u20130.6) and 0.1 (0\u20130.2) per year, respectively] than those in the titin\u2013 group [0 (0\u20130.2) and 0 (0\u20130) per year, <jats:italic>p<\/jats:italic> = 0.004 and <jats:italic>p<\/jats:italic> = 0.006, respectively]. In multivariate analysis, positive anti-titin antibody was still significantly associated with multiple admissions [odds ratio (OR) 4.11, 95% CI 1.05\u201316.03] compared to the titin\u2013 group as a reference after adjusting for sex, follow-up duration, age at onset, systemic chemotherapy, and the Masaoka staging.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The presence of anti-titin antibody is associated with more frequent hospital utilization. Personalized explanation and careful monitoring strategy could be required in patients with thymoma-associated MG with anti-titin antibody for the timely detection of relapses.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fneur.2022.978997","type":"journal-article","created":{"date-parts":[[2022,10,5]],"date-time":"2022-10-05T08:32:59Z","timestamp":1664958779000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":13,"title":["Anti-titin antibody is associated with more frequent hospitalization to manage thymoma-associated myasthenia gravis"],"prefix":"10.3389","volume":"13","author":[{"given":"Ki Hoon","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seung Woo","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinhyuk","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hye Yoon","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ha Young","family":"Shin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,10,5]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"2570","DOI":"10.1056\/NEJMra1602678","article-title":"Myasthenia gravis","volume":"375","author":"Gilhus","year":"2016","journal-title":"N Engl J Med."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1016\/S1474-4422(15)00145-3","article-title":"Myasthenia gravis: subgroup classification and therapeutic strategies","volume":"14","author":"Gilhus","year":"2015","journal-title":"Lancet Neurol."},{"key":"B3","first-page":"159","article-title":"Myasthenia gravis","volume":"88","author":"Vincent","year":"2002","journal-title":"Adv Neurol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"e91816","DOI":"10.1371\/journal.pone.0091816","article-title":"Autoantibodies to agrin in myasthenia gravis patients","volume":"9","author":"Zhang","year":"2014","journal-title":"PLoS ONE."},{"key":"B5","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1126\/science.270.5234.293","article-title":"Titins: giant proteins in charge of muscle ultrastructure and elasticity","volume":"270","author":"Labeit","year":"1995","journal-title":"Science."},{"key":"B6","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1002\/mus.23774","article-title":"Striational antibodies in a paraneoplastic context","volume":"47","author":"McKeon","year":"2013","journal-title":"Muscle Nerve."},{"key":"B7","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1046\/j.1468-1331.1999.650555.x","article-title":"EMG evidence of myopathy and the occurrence of titin autoantibodies in patients with myasthenia gravis","volume":"6","author":"Somnier","year":"1999","journal-title":"Eur J Neurol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1007\/s00415-004-0479-z","article-title":"The significance of titin antibodies in myasthenia gravis\u2013correlation with thymoma and severity of myasthenia gravis","volume":"251","author":"Chen","year":"2004","journal-title":"J Neurol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1596","DOI":"10.1001\/archneur.57.11.1596","article-title":"The severity of myasthenia gravis correlates with the serum concentration of titin and ryanodine receptor antibodies","volume":"57","author":"Romi","year":"2000","journal-title":"Arch Neurol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.jneuroim.2016.07.001","article-title":"Autoantibody profile and clinical characteristics in a cohort of Chinese adult myasthenia gravis patients","volume":"298","author":"Hong","year":"2016","journal-title":"J Neuroimmunol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1046\/j.1468-1331.2003.00678.x","article-title":"Disease severity and outcome in thymoma myasthenia gravis: a long-term observation study","volume":"10","author":"Romi","year":"2003","journal-title":"Eur J Neurol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1097\/JTO.0000000000000654","article-title":"The 2015 World Health Organization Classification of Tumors of the Thymus: Continuity and Changes","volume":"10","author":"Marx","year":"2015","journal-title":"J Thorac Oncol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"S304","DOI":"10.1097\/JTO.0b013e3181f20c05","article-title":"Staging system of thymoma","volume":"5","author":"Masaoka","year":"2010","journal-title":"J Thorac Oncol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1212\/WNL.55.1.16","article-title":"Myasthenia gravis: recommendations for clinical research standards Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America","volume":"55","author":"Jaretzki","year":"2000","journal-title":"Neurology."},{"key":"B15","first-page":"331","article-title":"Paraneoplastic IgG striational autoantibodies produced by clonal thymic B cells and in serum of patients with myasthenia gravis and thymoma react with titin","volume":"66","author":"Williams","year":"1992","journal-title":"Lab Invest."},{"key":"B16","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1001\/archneur.58.6.885","article-title":"Anti-titin antibodies in myasthenia gravis: tight association with thymoma and heterogeneity of nonthymoma patients","volume":"58","author":"Yamamoto","year":"2001","journal-title":"Arch Neurol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1111\/ane.12271","article-title":"Anti-titin antibody in early- and late-onset myasthenia gravis","volume":"130","author":"Szczudlik","year":"2014","journal-title":"Acta Neurol Scand."},{"key":"B18","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1186\/s12883-020-01802-4","article-title":"Prospective study of stress, depression and personality in myasthenia gravis relapses","volume":"20","author":"Bogdan","year":"2020","journal-title":"BMC Neurol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"e000313","DOI":"10.1136\/bmjopen-2011-000313","article-title":"Factors associated with depressive state in patients with myasthenia gravis: a multicentre cross-sectional study","volume":"1","author":"Suzuki","year":"2011","journal-title":"BMJ Open."},{"key":"B20","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1007\/s13760-018-0915-y","article-title":"Quality of life in patients with MuSK positive myasthenia gravis","volume":"118","author":"Stankovic","year":"2018","journal-title":"Acta Neurol Belg."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1007\/s00415-010-5549-9","article-title":"Health-related quality of life in ALS, myasthenia gravis and facioscapulohumeral muscular dystrophy","volume":"257","author":"Winter","year":"2010","journal-title":"J Neurol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1002\/mus.26719","article-title":"Severity and depression can impact quality of life in patients with myasthenia gravis","volume":"61","author":"Alanazy","year":"2020","journal-title":"Muscle Nerve."},{"key":"B23","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1007\/s40273-020-00912-8","article-title":"Economic costs of myasthenia gravis: a systematic review","volume":"38","author":"Landfeldt","year":"2020","journal-title":"Pharmacoeconomics."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1212\/WNL.57.9.1579","article-title":"Do titin and cytokine antibodies in MG patients predict thymoma or thymoma recurrence?","volume":"57","author":"Buckley","year":"2001","journal-title":"Neurology."}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2022.978997\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,5]],"date-time":"2022-10-05T08:33:04Z","timestamp":1664958784000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2022.978997\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,5]]},"references-count":24,"alternative-id":["10.3389\/fneur.2022.978997"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2022.978997","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,5]]},"article-number":"978997"}}